

The Orange Shot

The Newsletter of the Orange County Immunization Coalition



Summer Fall 2023 EDITION

OCIC NEWSLETTER

For more information about OCIC please contact:
Jody Nguyen (714) 834-3131
Jnguyen@ochca.com

Highlights of this Issue

- ACIP Updates in the MMWR
- 2023-2024 COVID-19 Vaccine
- RSV Vaccines
- Pneumococcal Vaccines
- 2023-2024 Influenza Season

Data Corner—Hepatitis B Birth Dose

Orange County Healthcare Agency is working on analyzing CAIR2 data with the goal to asses immunization coverage for a variety of vaccines across Orange County. Our initial project has been to assess the % of Orange County children who received a dose of hepatitis be vaccine within the first three days after birth (a birth dose). We are currently assessing coverage and individual birthing facilities and will be working with these facilities to validate our data against birth facility records, with the goal of sharing that data in our next issue. The ACIP recommends that all infants weighing $\geq 2,000$ gm receive a birth dose within 24 hours of birth https://www.cdc.gov/mmwr/volumes/67/rr/rr6701a1.htm.

ACIP Updates in the MMWR

November 18, 2022 / No. 46

<u>Measles, Mumps, Rubella Vaccine (PRIORIX): Recommendations of the Advisory Committee on Immunization Practices — United States, 2022</u>

July 21, 2023 / Vol. 72 / No. 29

Use of Respiratory Syncytial Virus Vaccines in Older Adults: Recommendations of the Advisory Committee on Immunization Practices

August 25, 2023/ Vol. 72/ No. 34

<u>Use of Nirsevimab for the Prevention of Respiratory Syncytial Virus Disease Among Infants and Young Children: Recommendations of the Advisory Committee on Immunization Practices — United States, 202</u>

Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practice – United States, 2023-2024 Influenza Season

September 8, 2023 / Vol. 72/ No. 3

Pneumococcal Vaccine for Adults Aged ≥19 Years: Recommendations of the Advisory Committee on Immunization Practices, US 2023

September 29, 2023 / Vol. 72 / No.39

Recommendations for Use of 20-Valent Pneumococcal Conjugate Vaccine in Children — United States, 2023

October 13, 2023 / Vol. 72

 $\underline{ \text{Use of Updated COVID-19 Vaccines 2023-2024 Formula for Persons Aged} \geq 6 \, \text{Months: Recommendations of the Advisory Committee on Immunization Practices} \\ - \text{United States, September 2023}$

Use of the Pfizer Respiratory Syncytial Virus Vaccine During Pregnancy for the Prevention of Respiratory Syncytial Virus—Associated Lower Respiratory Tract Disease in Infants: Recommendations of the Advisory Committee on Immunization Practices — United States, 2023

Education Update

California Department of Public Health (CDPH) is now running a Weekly CDPH Immunization Update for Providers every Friday from 9:00-10:30. These sessions will cover a wide range of immunization topics and includes time to ask CDPH immunization experts your questions. Click here to register to attend.

2023-2024 COVID Vaccine

On September 12, 2023, the CDC's Advisory Committee on Immunization Practices (ACIP) voted in favor recommendations for the use of the new 2023-2024 COVID vaccine. The latest vaccine is a monovalent vaccine formulated to more closely match the strains of SARS-CoV-2 anticipated to circulate this winter. Everyone six-months and older should receive at least one dose of the 2023-2024 vaccine. Unvaccinated children six-months through 4 years

of age needs to complete a primary series consisting of three doses of Pfizer—BioNtech or two doses of the Moderna vaccine. Children in this age group should receive all doses using doses from the same manufacturer. Children 6 months through 4 years of age who have previously been vaccinated are recommended to receive 1 or 2 doses depending on history and timing of previous COVID vaccine doses. Immunocompromised individuals may be eligible for additional doses. Those 12 years and older who have not received a 2023-2024 mRNA vaccine they may receive an 2023-2024 Novavax COVID-19; previously unvaccinated individuals may receive two Novavax doses. See the CDC's Interim Clinical Considerations for Use of COVID-19 Vaccines in the United States for the complete guidance.

As was discussed in our previous issue COVID-19 vaccines are now distributed though the commercial marketplace. Patients should discuss with their provider who usually administers vaccines about availability. Providers should use their usual channels, such as manufacturers or distributors. The federal government is funding COVID-19 vaccines for uninsured and underinsured individuals through some pharmacies and Federally Qualified Community Health Centers. One can search at Vaccines.gov to find a site near you.



The Orange Shot

The Newsletter of the Orange County Immunization Coalition




Summer/Fall 2023 EDITION

OCIC NEWSLETTER

For more information about OCIC please contact:
Jody Nguyen (714) 834-3131
Jnguyen@ochca.com

Respiratory Synsitial Virus (RSV) vaccines



RSV is a seasonal respiratory that is the leading cause of hospitalization among U.S. infants. In addition, each season RSV has been estimated to cause between 60,000 - 160,000 hospitalizations and 6,000 - 10,000 deaths among adults aged ≥ 65 years older adults. This year new opportunities are available to decrease the burden of RSV hospitalizations in both of these groups.

On June 21, 2023 the ACIP recommended that adults aged \geq 60 years may receive a single dose of RSV vaccine in the context of shared decision-making between patients and their provider.

On August 3, 2023 the ACIP recommended the use of a dose Nirsevimab (a long-acting monoclonal antibody, for the prevention of RSV) for all infants aged < 8 months who are born during or entering their first RSV season and for infants and children 8-19 months wo are at increased risk for severe RSV disease and are entering their second season. On September 22, 2023, CDC recommended the RSV vaccine for pregnant people at 32 through 36 weeks gestation during the months of September—January to prevent RSV lower respiratory tract infection in infants, (MMWR October 13, 2023/72(41);115-1122). In additional to RSV vaccine, continue to strongly recommend updated COVID vaccine and flu vaccines as well as Tdap (at 27-36 weeks gestation). It is safe to co-administer RSV, COVID, flu, and Tdap on the same day. Most infants born to mothers who received a dose of RSV vaccine during their recent pregnancy do not need a dose of Nirsevimab. While Nirsevimab is not a traditional active immunization vaccine, the administration of monoclonal antibodies is a means of passive immunization. Nirsevimab is available through the Vaccines for Children (VFC) for those who are VFC eligible.

Pneumococcal Conjugate Vaccines



This year the ACIP approved recommendations for the use of 20-valent pneumococcal vaccine (PCV20) for children and adults.

For children 2-23 months of age, either 15—valent pneumococcal conjugate vaccine PCV15 or PCV20 may be used following the currently recommended schedule..

Children age 2-18 years with any <u>risk conditions</u> may be eligible for a dose of PCV20 depending on their prior pneumococcal vaccination history.

For adults the ACIP recommendations specify the use of either PCV20 alone or PCV15 in series with 23 -valent pneumococcal polysaccharide vaccine (PPSV23) for all adults age > 65 years and for adults aged

19-64 with certain underlying conditions or other risk factors who have not received a PCV or whose vaccination is unknown. ACIP recommends use of either a single dose of PCV20 or ≥1 dose of PPSV23 for adults who have started their pneumococcal vaccine series with PCV13 but have not received all recommended PPSV23 doses. Shared clinical decision-making is recommended regarding use of a supplemental PCV20 dose for adults aged ≥65 years who have completed their recommended vaccine series with both PCV13 and PPSV23.

Schools, Child Care Sites and Vaccines

A reminder that the California Department of Public Health (CDPH) has moved the school reporting to the <u>CAIR Hub</u>. In addition, CDPH wants to remind school and Child Cares that the deadline for submitting data related to required vaccinations is December 1, 2023.

Seasonal Influenza Vaccine

A reminder that it is time to vaccinate against seasonal influenza virus. The significant update from the ACIP was that even individuals with a history of severe egg allergy are eligible to receive any of the age appropriate seasonal influenza vaccines. Influenza vaccination should be offered thought the end of the season. Finally, to remind health care providers and emergency responders, that there are Orange County Health Officer Orders mandating they be vaccinated against seasonal influenza unless they have a medical or religious exemption.